Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-09-2014 | Case Report

A Case of AML-M2 with Sole Interstitial Deletion in 9q Without AML1–ETO/Inv 16 Rearrangement and FLT3/NPMI Mutations

Authors: G. Sandhya Devi, Faiq Ahmed, Manasi C. Mundada, S. Sudha Murthy, Krishna Mohan Mallavarapu

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2014

Abstract

Conventional/molecular cytogenetics is important in identification of genomic abnormalities, for prognostication and in risk stratification of de novo patients with acute myeloid leukemias (AML). Here we present an AML M2 case showing the sole karyotypic abnormality, the rare interstitial deletion in the long arm of chromosome 9 with the loss of segment q12–q13.

Raimondi SC (2006) Cytogenetics of acute leukemias. In: Pui CH (ed) Childhood leukemias, 2nd edn. Cambridge University Press, New York, pp 235–271

Vardiman JW, Thiele J, Arber AD, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):51–937CrossRef

Naeim F, Rao PN (2008) Acute myeloid leukemia. In: Naeim F, Rao PN, Grody WW (eds) Hematopathology morphology, immunophenotype, cytogenetics, and molecular approaches, 1st edn. Elsevier, Amsterdam, pp 207–255

Viguie F (1998) Del (9q) solely. Atlas Genet Cytogenet Oncol Haematol. URL:http://AtlasgeneticsOncolgy.org/

Peniket A, Wainscoat J, Side L, Daly S, Kusec R, Buck G, Wheatley K, Walker H, Chatters S, Harrison C, Boultwood J, Goldstone A, Burnett A (2005) Del (9q) AML: clinical and cytological characteristics and prognostic implications. Haematology 129(2):210–220

Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud O (2011) Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol 2011:104631PubMedCrossRefPubMedCentral

Kar B, Dhanalakshmi KG, Revathi R (2008) Interstitial deletion of 9q in a case of acute myeloid leukemia with t(8;21). Indian J Hematol Blood Transfus 24(2):75–77PubMedCrossRefPubMedCentral

Shaffer LGSM, Campbell LJ (eds) (2009) ISCN 2009: An international system for human cytogenetic nomenclature. S Karger, Basel

Ahmad F, Dalvi R, Das BR, Mandava S (2008) Specific chromosomal aberrations in de novo acute myeloid leukemia: a comparative analysis of results with a report of three novel chromosomal rearrangements t(7;14)(q35;q13), t(8;18)(p11.2;q12), t(13;15) in Indian population. Cancer Detect Prev 32(2):77–168CrossRef

10.

Bakshi SR, Roy SK, Trivedi PJ, Brahmbhatt MM, Rawal SM, Kakadia PM, Bhatt SS (2004) AML-M2 with der(18)t(1;18)(q2?;p11.3) in addition to t(8; 21) and del(9q). Indian J Hum Genet 10(2):78–80

11.

Sweetser DA, Peniket AJ, Haaland C et al (2005) Delineation of the minimal commonly deleted segment and identification of candidate tumor suppressor genes in del (9q) acute myeloid leukemia. Genes Chromosom Cancer 44(3):279–291PubMedCrossRef

12.

Dayyani F, Wang JF, Yeh JRJ, Ahn EN, Tobey E, Zhang DE et al (2008) Loss of TLE1 and TLE4 from the del (9q) commonly deleted region in AML cooperates with AML1–ETO to affect myeloid cell proliferation and survival. Blood 111(8):47–4338CrossRef

13.

Fröhling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D et al (2005) Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosom Cancer 42(4):32–427

14.

Boonthimat C, Thongnoppakhun W, Auewarakul CU (2008) Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica 93:69–1565CrossRef

Title: A Case of AML-M2 with Sole Interstitial Deletion in 9q Without AML1–ETO/Inv 16 Rearrangement and FLT3/NPMI Mutations
Authors: G. Sandhya Devi
Faiq Ahmed
Manasi C. Mundada
S. Sudha Murthy
Krishna Mohan Mallavarapu
Publication date: 01-09-2014
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2014
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-013-0322-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2014

Extranodal NK/T Cell Lymphoma of the Jejunum Complicated by Hemophagocytic Syndrome: Practical Problems Encountered by a Pathologist

Multicentric, Hyaline Vascular Variant of Castleman’s Syndrome

Paraplegia: An Unusual Presentation of Follicular Lymphoma

Chronic Neutrophilic Leukemia: A Rare Case Report

Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient

A Novel WASP Gene Mutation in a Chinese Boy with Wiskott–Aldrich Syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer